ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

adagrasib

Also written as “Adagrasib”, “MRTX849” and “Eltrombopag + adagrasib”.

Its studies are mostly in Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Biliary Tract Neoplasms, led by 2 companies.

Drug pageAdagrasib: every studyAll 28 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 28, 202016 company-led studies, 7 open or runningNext primary completion: Feb 16, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only157 open or runningphase 3since Oct 28, 2020Dec 18, 2018Feb 16, 2028phase 2 · NCT07415031
Zai Lab10 open or runningphase 1since Jan 13, 2022Jan 13, 2022none ahead

Also a collaborator on its studies: Aadi Bioscience, Novartis and Boehringer Ingelheim.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Zai Lab only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2020Named adagrasibINNProposed as its International Nonproprietary Name in WHO's List 124 · before, MRTX849
  2. Jan 13, 2022First study: phase 1 study in Neoplasm MetastasisFirst studyNCT05263986 · 22 enrolled · China

TargetBeta

KRAS →read by rule
“An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule
“GTPase KRas inhibitor”ChEMBL 37, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36
opnurasibruleNovartisphase 35

Studies

The one study Zai Lab leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05263986Neoplasm Metastasis · China1UNKNOWNOct 31, 202322

How it is read

Names in the registry

  • “Adagrasib”, 12 entries
  • “MRTX849”, 7 entries
  • “Eltrombopag + adagrasib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.